Executives representing seven of the world’s top pharmaceutical companies have agreed to testify on drug prices before the Senate Finance Committee this month, and STAT senior writer Ed Silverman in a column says not doing so would be “foolish.”
“Showing up is simply smart politics in the face of proposals and legislation that could change the way they do business,” he writes.
The hearing is slated for Feb. 26.
Policymakers are expected to put pressure on the executives regarding high drug prices.
” … These guys — and one woman, Johnson & Johnson’s Jennifer Taubert — will face antagonists, notably, committee chair Chuck Grassley (R-Iowa), who has a history of making pharma uncomfortable,” Silverman writes.
To read Silverman’s full column on STAT, click here.